Related Experiment Video
Updated: May 18, 2026
08:35
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
[Azilsartan: a new angiotensin receptor blocker]
1Department of Geriatric Medicine and Nephrology, Osaka University Graduate School of Medicine.
Nihon Rinsho. Japanese Journal of Clinical Medicine
|September 28, 2012
Summary
Azilsartan, a novel angiotensin II receptor blocker (ARB), offers superior 24-hour blood pressure control and improved insulin resistance compared to other ARBs. This antihypertensive agent demonstrates potent efficacy and safety in clinical studies.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
- Nephrology
Context:
- Hypertension is a global health issue requiring effective long-term management.
- Angiotensin II Receptor Blockers (ARBs) are a cornerstone of antihypertensive therapy.
- Comparing the efficacy and safety of newer ARBs is crucial for clinical practice.
Purpose:
- To evaluate the pharmacological profile and clinical efficacy of azilsartan.
- To compare azilsartan's antihypertensive effects with other ARBs in Japanese hypertensive patients.
- To assess azilsartan's impact on insulin resistance and urinary albumin excretion.
Summary:
- Azilsartan exhibits potent and specific angiotensin II receptor binding inhibition, leading to continuous antagonism.
- Clinical studies show once-daily azilsartan provides superior 24-hour sustained antihypertensive effects compared to candesartan with equivalent safety.
- Pre-clinical data indicate azilsartan more effectively improves insulin resistance and suppresses urinary albumin excretion than other ARBs.
Impact:
- Azilsartan represents a unique antihypertensive agent with enhanced pharmacological activity.
- The drug offers the potential for higher rates of 24-hour hypertension control with once-daily dosing.
- Azilsartan's beneficial effects on metabolic parameters and renal function may extend its therapeutic applications.
Related Concept Videos
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:28Hypertension IV: Drug Therapy and Lifestyle Modifications
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...